773 related articles for article (PubMed ID: 2516809)
21. [The diagnostic significance of finding a M-component in serum].
Schmidt EB; Møller-Petersen J
Ugeskr Laeger; 1986 Mar; 148(11):633-5. PubMed ID: 3083549
[No Abstract] [Full Text] [Related]
22. Monoclonal gammopathies of undetermined significance.
Kyle RA; Rajkumar SV
Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic criteria of multiple myeloma.
Kyle RA
Hematol Oncol Clin North Am; 1992 Apr; 6(2):347-58. PubMed ID: 1582977
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology of monoclonal gammopathy in Morocco - A hospital-based study.
Ouzzif Z; Doghmi K; Messaoudi N; Bouhsain S; El Machtani S; Biaz A; Rachid A; Dami A; Bezza A; El Maataoui A
Cancer Rep (Hoboken); 2023 May; 6(5):e1814. PubMed ID: 36999311
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
28. "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up.
Kyle RA
Mayo Clin Proc; 1993 Jan; 68(1):26-36. PubMed ID: 8417251
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
Schmidt T; Callander N
J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
[TBL] [Abstract][Full Text] [Related]
30. The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients.
Cao XX; Meng Q; Mao YY; Su W; Zhen JF; Shen KN; Zhang CL; Huang XF; Duan MH; Zhang W; Zhu TN; Cai HC; Chen M; Zhou DB; Li J
Leuk Res; 2016 Jul; 46():85-8. PubMed ID: 27232065
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma.
Kyle RA
Hematol Oncol Clin North Am; 1997 Feb; 11(1):71-87. PubMed ID: 9081205
[TBL] [Abstract][Full Text] [Related]
33. The spectrum of IgM monoclonal gammopathy in 430 cases.
Kyle RA; Garton JP
Mayo Clin Proc; 1987 Aug; 62(8):719-31. PubMed ID: 3110508
[TBL] [Abstract][Full Text] [Related]
34. Smoldering multiple myeloma current treatment algorithms.
Rajkumar SV; Kumar S; Lonial S; Mateos MV
Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
[TBL] [Abstract][Full Text] [Related]
35. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
36. The search for meaning in monoclonal protein. Is it multiple myeloma or monoclonal gammopathy of undetermined significance?
Brigden ML
Postgrad Med; 1999 Aug; 106(2):135-42; quiz 185. PubMed ID: 10456045
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
38. Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia.
Atrash S; Zhang Q; Papanikolaou X; Stein C; Abdallah AO; Barlogie B
J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241189
[TBL] [Abstract][Full Text] [Related]
39. The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
Emery A; Moore S; Crowe J; Murray J; Peacock O; Thompson D; Betts F; Rapps S; Ross L; Rothschild-Rodriguez D; Arana Echarri A; Davies R; Lewis R; Augustine DX; Whiteway A; Afzal Z; Heaney J; Drayson MT; Turner JE; Campbell JP
BMC Cancer; 2024 Feb; 24(1):174. PubMed ID: 38317104
[TBL] [Abstract][Full Text] [Related]
40. Clinical practice. Monoclonal gammopathy of undetermined significance.
Bladé J
N Engl J Med; 2006 Dec; 355(26):2765-70. PubMed ID: 17192542
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
